A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Clinical trial NCT01745965 · COMPLETED
Trial details
- NCT number
- NCT01745965
- Sponsor
- Women's Cancer Study Group GmbH
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-01
- Primary completion
- 2015-02-01
- Enrollment
- 380
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.